SARS CoV 2 News and Research

RSS

Vaccinated individuals previously infected with SARS-CoV-2 show robust neutralization of the B.1.1.7 variant

New research published in the journal Viruses suggests recovering from a coronavirus disease 2019 (COVID-19) infection provides immunity against the B.1.1.7 (or UK) variant. The time when the previous infection took place and the variant involved in prior infection influenced cross-neutralization.

23 Jun 2021

Study shows equitable allocation strategies for SARS-CoV-2 vaccines have a comparative edge

In a recent paper, US researchers demonstrate that equitable distributions of vaccines against COVID-19 are a very optimal approach.

23 Jun 2021

Longitudinal study finds SARS-CoV-2 neutralizing antibodies decline a year after infection

Research led by Xin Zheng of Huazhong University of Science and Technology in Wuhan, China, found that about 90% of patients who recovered from COVID-19 continued to have IgG antibodies targeting the N-domain and receptor-binding domain of the spike protein. However, approximately 43% of patients showed signs of neutralizing antibody activity.

23 Jun 2021

Researchers review the origins of SARS-CoV-2 and present treatment methods

A million more questions arise for every answer we have against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Where did it come from? And will it ever go away? A recent article published in Frontiers in Cellular and Infection Microbiology reviews what scientists currently know about the origin, SARS-CoV-2 structure, and potential treatments against this new virus.

23 Jun 2021

Genome surveillance tool facilitates detection of COVID-19 variants

Swedish researchers have developed COVseq, a SARS-CoV-2 genome tracker that can be produced at a large scale for a small cost.

23 Jun 2021

Airborne pollen grains facilitate spread of COVID-19 by carrying SARS-CoV-2 particles

Computer models simulating the movement of pollen grains from trees in crowded areas could accelerate the spread of COVID-19.

23 Jun 2021

New study enrolls young adults to evaluate SARS-CoV-2 infection

The Prevent COVID U study, which launched in late March 2021 to evaluate SARS-CoV-2 infection and transmission among university students vaccinated with the Moderna COVID-19 Vaccine, has expanded beyond the university setting to enroll young adults ages 18 through 29 years and will now also include people in this age group who choose not to receive a vaccine.

23 Jun 2021

Vaccine side effects should be viewed as a sign of efficacy, say immunologists

The rapid development of safe and efficacious vaccines against SARS-CoV-2 has offered hope that the global COVID-19 pandemic may soon be under control. However, vaccinations remain incomplete in many developed nations, and lag further still in the developing world.

23 Jun 2021

More than 16 million Americans had undiagnosed SARS-CoV-2 infections during first wave

As many as 16.8 million Americans had undiagnosed SARS-CoV-2 infections - 5 times the rate of diagnosed infections - by the end of July of 2020, according to an analysis of antibodies from more than 8,000 previously undiagnosed adults collected during the pandemic's first wave.

23 Jun 2021

GenScript and Duke-NUS announce notice of allowance for “Surrogate Virus Neutralization Technology”

GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a world-leading life sciences research and application service and product provider, and Duke-NUS Medical School, a premier, research intensive medical school, announced today that the U.S. Patent and Trade Office has issued a notice of allowance for the patent application for a novel Surrogate Virus Neutralization Technology (sVNT).

23 Jun 2021

Study provides treatment guidance for children and adolescents with multisystem inflammatory syndrome

An analysis conducted by a group of investigators including Tamara Bradford, MD, Associate Professor of Pediatrics at LSU Health New Orleans School of Medicine, found that children and adolescents with Multisystem inflammatory syndrome in children (MIS-C) initially treated with intravenous immune globulin (IVIG) plus glucocorticoids had a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

22 Jun 2021

Molecular study reveals signs of inflammation in brains of people who died of COVID-19

The most comprehensive molecular study to date of the brains of people who died of COVID-19 turned up unmistakable signs of inflammation and impaired brain circuits.

22 Jun 2021

New universal vaccine protects mice against COVID-19 and other coronaviruses

Scientists at the University of North Carolina Gillings School of Global Public Health have developed a universal vaccine that protected mice not just against COVID-19 but also other coronaviruses and triggered the immune system to fight off a dangerous variant.

22 Jun 2021

Engineering nanobodies to fight against the SARS-CoV-2 virus

Scientists are pursuing a new strategy in the protracted fight against the SARS-CoV-2 virus by engineering nanobodies that can neutralize virus variants in two different ways.

22 Jun 2021

Do the Moderna and Pfizer COVID-19 vaccines elicit different antibody responses?

A recent study led by scientists from the United States has compared the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response among clinicians who have been immunized with Pfizer/BioNTech or Moderna coronavirus disease 2019 (COVID-19) vaccine.

22 Jun 2021

What is the optimal dosing regimen for remdesivir in COVID-19 patients? A computational model

A team of scientists from the Pennsylvania State University, USA, recently analyzed the pharmacodynamics and pharmacokinetics of antiviral drug remdesivir using computational models. Based on the study findings, which are yet to be peer-reviewed, the scientists recommend that for effective inhibition of SARS-CoV-2 infection, remdesivir should be used with other antiviral medicines, or its dosing regimen should be optimized to improve bioavailability.

22 Jun 2021

Research findings on the links between air pollution and neurodegeneration

There is growing awareness that air pollutants are playing a critical role in the development of neurodegenerative diseases.

22 Jun 2021

Is liquid chalk an effective disinfectant of SARS-CoV-2 and influenza viruses?

A recent study, published in the American Society for Microbiology’s journal, mSphere, evaluated the use of many liquid chalk products as antiseptics against the transmission of highly pathogenic human viruses such as influenza A virus (H1N1), SARS-CoV-2, (IAV), and norovirus in a mouse norovirus (MNV) model. The researchers applied chalk before or after virus inoculum and determined the recovery of infectious virus to mimic its use in the gym setting.

22 Jun 2021

Have maternal pre-pandemic stress levels influenced children’s mental health during the COVID-19 pandemic?

A recent study, published in Child and Adolescent Psychiatry and Mental Health, assessed the role of maternal daily perceived stress on the mental health of children during the pandemic.

22 Jun 2021

Researchers screen Chinese herbal medicines and plant compounds for anti-SARS-CoV-2 activity

A review published in Phytotherapy Research discussed the natural anti-SARS-CoV-2 products identified based on in silico prediction. The review’s authors also illustrate the impact of many phytochemicals either alone or in combination with traditional treatments and their potential molecular mechanisms involved in SARS-CoV-2 prevention and treatment.

22 Jun 2021

SARS CoV 2 News and Research

Vaccinated individuals previously infected with SARS-CoV-2 show robust neutralization of the B.1.1.7 variant

Study shows equitable allocation strategies for SARS-CoV-2 vaccines have a comparative edge

Longitudinal study finds SARS-CoV-2 neutralizing antibodies decline a year after infection

Researchers review the origins of SARS-CoV-2 and present treatment methods

Genome surveillance tool facilitates detection of COVID-19 variants

Airborne pollen grains facilitate spread of COVID-19 by carrying SARS-CoV-2 particles

New study enrolls young adults to evaluate SARS-CoV-2 infection

Vaccine side effects should be viewed as a sign of efficacy, say immunologists

More than 16 million Americans had undiagnosed SARS-CoV-2 infections during first wave

GenScript and Duke-NUS announce notice of allowance for “Surrogate Virus Neutralization Technology”

Study provides treatment guidance for children and adolescents with multisystem inflammatory syndrome

Molecular study reveals signs of inflammation in brains of people who died of COVID-19

New universal vaccine protects mice against COVID-19 and other coronaviruses

Engineering nanobodies to fight against the SARS-CoV-2 virus

Do the Moderna and Pfizer COVID-19 vaccines elicit different antibody responses?

What is the optimal dosing regimen for remdesivir in COVID-19 patients? A computational model

Research findings on the links between air pollution and neurodegeneration

Is liquid chalk an effective disinfectant of SARS-CoV-2 and influenza viruses?

Have maternal pre-pandemic stress levels influenced children’s mental health during the COVID-19 pandemic?

Researchers screen Chinese herbal medicines and plant compounds for anti-SARS-CoV-2 activity

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News